Finorex 10 mg (Tablet)
Unit Price: ৳ 65.00 (1 x 10: ৳ 650.00)
Strip Price: ৳ 650.00
Medicine Details
| Category | Details |
|---|---|
| Generic | Finerenone |
| Company | Ziska pharmaceuticals ltd |
| Also available as |
Indications
reduce the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death, nonfatal myocardial infarction, and hospitalization for heart failure in adult patients with chronic kidney disease (CKD) associated with type 2 diabetes (T2D)
Pharmacology
- nonsteroidal
- selective antagonist of mineralocorticoid receptor (MR)
- blocks MR mediated sodium reabsorption
- high potency and selectivity for MR
- minimal affinity for other receptors
- reduces systolic and diastolic blood pressure
- completely absorbed after oral administration
- metabolized by CYP3A4 and CYP2C8
- excreted in urine
Dosage & Administration
- recommended starting dosage of 10 mg or 20 mg orally once daily
- dosage adjustment based on eGFR and serum potassium levels
- tablet can be crushed for patients who can't swallow whole tablets
- monitoring and dose adjustment of serum potassium levels required
- instructions for missed doses
Interaction
- contraindicated with strong CYP3A4 inhibitors
- monitor serum potassium with moderate and weak CYP3A4 inhibitors
- avoid concomitant use with strong or moderate CYP3A4 inducers
Contraindications
- contraindicated in concomitant use with strong CYP3A4 inhibitors
- contraindicated in patients with adrenal insufficiency
Side Effects
- adverse reactions include hyperkalemia, hypotension, and hyponatremia
Pregnancy & Lactation
- no available data on use in pregnancy
- animal studies show developmental toxicity
- no data on presence in human milk
Precautions & Warnings
- risk of hyperkalemia increases with decreasing kidney function
- measure serum potassium and eGFR before initiation of treatment
- do not initiate if serum potassium is > 5.0 mEq/L
- more frequent monitoring for patients at risk for hyperkalemia
Use in Special Populations
- Pediatric Use: safety and efficacy not established below 18 years of age
- Geriatric Use: no differences in safety or efficacy observed in patients 65 years and older
- Hepatic Impairment:
- avoid in severe hepatic impairment
- no dosage adjustment in mild or moderate hepatic impairment
Overdose Effects
suspected overdose should lead to immediate treatment interruption, likely manifestation is hyperkalemia
Therapeutic Class
Mineralocorticoid Receptor Antagonists
Storage Conditions
- keep below 30°C temperature
- away from light and moisture
- keep out of the reach of children